BeyondSpring (BYSI) Competitors

Humacyte (NASDAQ:HUMA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Which has preferable valuation and earnings, HUMA or BYSI?

BeyondSpring has higher revenue and earnings than Humacyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$1.57M	225.27	-$148.70M	-$0.69	-3.30
BeyondSpring	$1.75M	53.22	-$11.12M	N/A	N/A

Do insiders & institutionals believe in HUMA or BYSI?

44.7% of Humacyte shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 5.1% of Humacyte shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, HUMA or BYSI?

Humacyte has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Does the media favor HUMA or BYSI?

In the previous week, Humacyte had 6 more articles in the media than BeyondSpring. MarketBeat recorded 7 mentions for Humacyte and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.38 beat Humacyte's score of 0.48 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
BeyondSpring	Positive

Is HUMA or BYSI more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	N/A	-73.59%
BeyondSpring	N/A	N/A	N/A

Do analysts prefer HUMA or BYSI?

Humacyte presently has a consensus price target of $11.71, suggesting a potential upside of 413.78%. Given Humacyte's stronger consensus rating and higher probable upside, research analysts plainly believe Humacyte is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
BeyondSpring	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Humacyte beats BeyondSpring on 8 of the 13 factors compared between the two stocks.